Browsing by Author "Kubica, Jacek"

Now showing items 1-8 of 8

    • Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: A systematic review and meta-analysis 

      Navarese, Eliano P; Lansky, Alexandra; Kereiakes, Dean; Kubica, Jacek; Gurbel, Paul A; Gorog, Diana; Valgimigli, Marco; Curzen, Nick; Kandzari, David. E.; Bonaca, Marc; Brouwer, Marc; Umińska, Julia M; Jaguszewski, Milosz; Raggi, Paolo; Waksman, Ron; Leon, Martin B.; Wijns, William; Andreotti, Felicita (2021-05-18)
      Aims:The value of elective coronary revascularisation plus medical therapy over medical therapy alone in managing stable patients with coronary artery disease is debated. We reviewed all trials comparing the two strategies ...

    • Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction : A prospective, observational, single-centre study 

      Adamski, Piotr; Sikora, Joanna; Laskowska, Ewa; Buszko, Katarzyna; Ostrowska, Małgorzata; Umińska, Julia M; Sikora, Adam; Skibińska, Natalia; Sobczak, Przemysław; Adamska, Urszula; Rość, Danuta; Kubica, Aldona; Paciorek, Przemysław; Marszałł, Michał P; Navarese, Eliano P; Gorog, Diana A; Kubica, Jacek (2017-10-12)
      BACKGROUND: Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation ...

    • Endogenous fibrinolysis - relevance to clinical thrombosis risk assessment 

      Kanji, Rahim; Kubica, Jacek; Navarese, Eliano P; Gorog, Diana (2020-12-09)
      The development of an obstructive luminal thrombus is pathological and considered a failure of endogenous fibrinolysis. The consequences may be fatal, or result in lasting downstream organ damage. Therefore, assessment of ...

    • Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention : A Meta-Analysis 

      Gue, Ying; Spinthakis, Nikolaos; Farag, Mohamed; Kubica, Jacek; Siller-Matula, Jolanta M; Srinivasan, Manivannan; Gorog, Diana (2020-01-28)
      Opiates are the traditional analgesics used in patients with ST-elevation myocardial infarction (STEMI). Pharmacodynamic studies indicate that opiates delay the absorption of orally administered P2Y 12 inhibitors and the ...

    • Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial 

      Kubica, Jacek; Adamski, Piotr; Gorog, Diana A.; Kubica, Aldona; Jilma, Bernd; Budaj, Andrzej; Siller-Matula, Jolanta M.; Gurbel, Paul A.; Alexopoulos, Dimitrios; Badarienė, Jolita; Dąbrowski, Paweł; Dudek, Dariusz; Giannitsis, Evangelos; Horszczaruk, Grzegorz; Jaguszewski, Miłosz J.; James, Stefan; Jeong, Young Hoon; Kryjak, Michał; Niezgoda, Piotr; Ostrowska, Małgorzata; Patti, Giuseppe; Romanek, Janusz; Di Somma, Salvatore; Specchia, Giuseppe; Tantry, Udaya; Gąsior, Mariusz; Tycińska, Agnieszka; Wojakowski, Wojciech; Buszko, Katarzyna; Gil, Robert; Gruchała, Marcin; Kasprzak, Jarosław; Kleinrok, Andrzej; Legutko, Jacek; Lesiak, Maciej; Navarese, Eliano P. (2021-09-30)

    • Metabolism of ticagrelor in patients with acute coronary syndromes. 

      Adamski, Piotr; Buszko, Katarzyna; Sikora, Joanna; Niezgoda, Piotr; Barańska, Malwina; Ostrowska, Małgorzata; Paciorek, Przemysław; Navarese, Eliano P; Gorog, Diana; Kubica, Jacek (2018-09-06)
      Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation ...

    • A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study 

      Kubica, Jacek; Adamski, Piotr; Niezgoda, Piotr; Kubica, Aldona; Podhajski, Przemysław; Barańska, Malwina; Umińska, Julia M.; Pietrzykowski, Łukasz; Ostrowska, Małgorzata; Siller-Matula, Jolanta M.; Badarienė, Jolita; Bartuś, Stanisław; Budaj, Andrzej; Dobrzycki, Sławomir; Fidor, Łukasz; Gąsior, Mariusz; Gessek, Jacek; Gierlotka, Marek; Gil, Robert; Gorący, Jarosław; Grzelakowski, Paweł; Hajdukiewicz, Tomasz; Jaguszewski, Miłosz; Janion, Marianna; Kasprzak, Jarosław; Kern, Adam; Klecha, Artur; Kleinrok, Andrzej; Kochman, Wacław; Krakowiak, Bartosz; Legutko, Jacek; Lesiak, Maciej; Nosal, Marcin; Piotrowski, Grzegorz; Przybylski, Andrzej; Roleder, Tomasz; Skonieczny, Grzegorz; Sobieszek, Grzegorz; Tycińska, Agnieszka; Wojciechowski, Dariusz; Wojakowski, Wojciech; Wójcik, Jarosław; Zielińska, Marzenna; Żurakowski, Aleksander; Specchia, Giuseppe; Gorog, Diana A.; Navarese, Eliano P. (2021-06-02)
      The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment ...

    • PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection 

      Navarese, Eliano P.; Podhajski, Przemysław; Gurbel, Paul A.; Grzelakowska, Klaudyna; Ruscio, Eleonora; Tantry, Udaya; Magielski, Przemysław; Kubica, Aldona; Niezgoda, Piotr; Adamski, Piotr; Junik, Roman; Przybylski, Grzegorz; Pilaczyńska-Cemel, Marta; Rupji, Manali; Specchia, Giuseppe; Pinkas, Jarosław; Gajda, Robert; Gorog, Diana A.; Andreotti, Felicita; Kubica, Jacek (2023-01-24)
      Background The intensity of inflammation during COVID-19 is related to adverse outcomes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in low-density lipoprotein receptor homeostasis, with potential ...